Literature DB >> 22205738

Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells.

Michael J Courchesne1, Maria C White, Brent A Stanfield, Arthur R Frampton.   

Abstract

The cytolytic animal virus equine herpesvirus type 1 (EHV-1) was evaluated for its oncolytic potential against five human glioblastoma cell lines. EHV-1 productively infected four of these cell lines, and the degree of infection was positively correlated with glioma cell death. No human major histocompatibility complex class 1 (MHC-I) was detected in the resistant glioma line, while infection of the susceptible glioma cell lines, which expressed human MHC-I, were blocked with antibody to MHC-I, indicating that human MHC-I acts as an EHV-1 entry receptor on glioma cells.

Entities:  

Mesh:

Year:  2011        PMID: 22205738      PMCID: PMC3302254          DOI: 10.1128/JVI.06296-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

Review 1.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

Review 2.  Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil.

Authors:  Franz J Zemp; Juan Carlos Corredor; Xueqing Lun; Daniel A Muruve; Peter A Forsyth
Journal:  Cytokine Growth Factor Rev       Date:  2010-05-18       Impact factor: 7.638

Review 3.  Selective MHC expression in tumours modulates adaptive and innate antitumour responses.

Authors:  R C Rees; S Mian
Journal:  Cancer Immunol Immunother       Date:  1999-10       Impact factor: 6.968

4.  Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

Authors:  Stuart A Grossman; Xiaobu Ye; Steven Piantadosi; Serena Desideri; Louis B Nabors; Myrna Rosenfeld; Joy Fisher
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

5.  Potential of equine herpesvirus 1 as a vector for immunization.

Authors:  Sascha Trapp; Jens von Einem; Helga Hofmann; Josef Köstler; Jens Wild; Ralf Wagner; Martin Beer; Nikolaus Osterrieder
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 7.  Advances in oncolytic virus therapy for glioma.

Authors:  Amy Haseley; Christopher Alvarez-Breckenridge; Abhik Ray Chaudhury; Balveen Kaur
Journal:  Recent Pat CNS Drug Discov       Date:  2009-01

8.  Reovirus therapy of tumors with activated Ras pathway.

Authors:  M C Coffey; J E Strong; P A Forsyth; P W Lee
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

9.  A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

Authors:  Peter Forsyth; Gloria Roldán; David George; Carla Wallace; Cheryl Ann Palmer; Don Morris; Gregory Cairncross; Maureen Vallee Matthews; James Markert; Yancey Gillespie; Matt Coffey; Brad Thompson; Mark Hamilton
Journal:  Mol Ther       Date:  2008-02-05       Impact factor: 11.454

10.  Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.

Authors:  Anhua Wu; Steve Wiesner; Jing Xiao; Katya Ericson; Wei Chen; Walter A Hall; Walter C Low; John R Ohlfest
Journal:  J Neurooncol       Date:  2006-11-01       Impact factor: 4.506

View more
  6 in total

1.  Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): infection with Equine Herpesvirus-1.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Helen Clare Roberts; Barbara Padalino; Paolo Pasquali; Hans Spoolder; Karl Ståhl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Andrea Carvelli; Romain Paillot; Alessandro Broglia; Lisa Kohnle; Francesca Baldinelli; Yves Van der Stede
Journal:  EFSA J       Date:  2022-01-12

2.  Equid Alphaherpesvirus 1 Modulates Actin Cytoskeleton and Inhibits Migration of Glioblastoma Multiforme Cell Line A172.

Authors:  Michalina Bartak; Marcin Chodkowski; Anna Słońska; Marta Grodzik; Jarosław Szczepaniak; Marcin W Bańbura; Joanna Cymerys
Journal:  Pathogens       Date:  2022-03-25

3.  Bovine herpesviruses induce different cell death forms in neuronal and glial-derived tumor cell cultures.

Authors:  Tereza C Cardoso; Ana Carolina G Rosa; Helena L Ferreira; Lucas H Okamura; Bruna R S M Oliveira; Flavia V Vieira; Camila Silva-Frade; Roberto Gameiro; Eduardo F Flores
Journal:  J Neurovirol       Date:  2016-06-16       Impact factor: 2.643

4.  Designing Herpes Viruses as Oncolytics.

Authors:  Cole Peters; Samuel D Rabkin
Journal:  Mol Ther Oncolytics       Date:  2015-07-22       Impact factor: 7.200

Review 5.  Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.

Authors:  Antonio Marchini; Eleanor M Scott; Jean Rommelaere
Journal:  Viruses       Date:  2016-01-06       Impact factor: 5.048

Review 6.  Programmed cell death: the battlefield between the host and alpha-herpesviruses and a potential avenue for cancer treatment.

Authors:  Chuankuo Zhao; Mingshu Wang; Anchun Cheng; Qiao Yang; Ying Wu; Dekang Zhu; Shun Chen; Mafeng Liu; XinXin Zhao; Renyong Jia; Kunfeng Sun; Xiaoyue Chen
Journal:  Oncotarget       Date:  2018-07-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.